To amend title XXVII of the Public Health Service Act and title XIX of the Social Security Act to require coverage of Alzheimer's biomarker testing under group health plans, group and individual health insurance coverage, and the Medicaid program.
Summary
HR9823, introduced July 22, 2026, would mandate coverage of Alzheimer's biomarker testing under group health plans, individual insurance, and Medicaid. The bill is in early committee stage with bipartisan cosponsorship. If enacted, it would increase utilization of diagnostic testing, benefiting clinical labs and imaging equipment providers.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9823 mandates coverage of Alzheimer's biomarker testing, which would increase test utilization.
- 2.Primary beneficiaries are diagnostic labs ($DGX, $LH) and PET imaging equipment makers ($GEHC).
- 3.Bill is in early committee stage; probability of passage is low-medium but bipartisan cosponsors improve chances.
Market Implications
The bill is at a procedural stage with no guaranteed passage. For investors, the primary signal is structural: Alzheimer's biomarker testing is a growing area, and a coverage mandate would accelerate adoption. $DGX and $LH offer direct exposure to the testing volume increase. $GEHC provides exposure to the imaging side. No price movement data is available to assess current market pricing, but the bill's early stage means minimal immediate impact.
Full Analysis
On July 22, 2026, Rep. Jake Auchincloss (D-MA) introduced HR9823, the 'Alzheimer's Biomarker Testing Coverage Act,' which amends the Public Health Service Act and Social Security Act to require coverage of Alzheimer's biomarker testing. The bill has been referred to the House Committee on Energy and Commerce. It currently has one bipartisan cosponsor, Rep. Juan Ciscomani (R-AZ). The legislative path is early—committee markup, floor vote, Senate passage, and presidential action are required for enactment.
The bill does not appropriate funds; it is a coverage mandate. Insurers and state Medicaid programs must cover tests such as blood-based biomarkers, CSF analysis, and amyloid PET imaging. This would shift costs from patients to payers, increasing utilization of existing tests.
No convergence was identified with recent presidential actions, as the only relevant executive order (Jul 13, 2026) focused on chemical manufacturing regulatory relief, a separate policy domain.
Structural winners are diagnostic labs and imaging equipment manufacturers. Quest Diagnostics ($DGX) and LabCorp ($LH) are the two largest independent clinical labs offering Alzheimer's biomarker tests. GE HealthCare ($GEHC) manufactures PET/CT scanners and radiotracers used in amyloid imaging. Insurers like UnitedHealth ($UNH) face increased costs but can adjust premiums, making the net effect neutral. The bill's early stage and lack of appropriations limit near-term market impact, but bipartisan support signals potential for progress.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Limited confirming evidence — causal thesis exists but few external signals
What the bill does
Mandate that group health plans, individual health insurance, and Medicaid programs cover Alzheimer's biomarker testing, including blood-based and CSF analysis.
Who must act
Health insurers and state Medicaid programs must reimburse for these tests.
What happens
Increased test utilization as patients gain coverage without out-of-pocket barriers, driving volume growth in clinical laboratory segments.
Stock impact
Quest Diagnostics is a leading independent clinical lab offering Alzheimer's blood tests (e.g., AD-Detect). Mandated coverage would expand the addressable patient pool, adding estimated $50M–$200M in annual revenue (less than 2% of total revenue) from neurology testing.
What the bill does
Same mandate—insurers and Medicaid must cover Alzheimer's biomarker testing.
Who must act
Health insurers and Medicaid programs.
What happens
Increased test volumes for LabCorp's Alzheimer's biomarker assays (e.g., amyloid beta, tau).
Stock impact
LabCorp offers a comprehensive Alzheimer's test menu including blood and CSF biomarkers. Full coverage would increase utilization, adding $40M–$150M in annual revenue (<1.5% of LabCorp's ~$12B revenue).
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Saving Lives and Reducing Health Care Waste by Improving Diagnosis in Medicine Act
EVEST Act
Precision Brain Health Research Act of 2026
ALERT Communities Act
Efficiency Adjustment Delay Act
Disabled Veterans Dignity Act of 2026
VA Fiscal Management Modernization Act
Veterans STAND Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →